Comparative chart of single and combination treatment options indicating which lipids can be targeted for dyslipidemias.
A team of investigators used a novel quantitative assessment to evaluate the effect pelacarsen on directly measured Lp(a)-C.
For patients with stroke of atherothrombotic origin, hypertriglyceridemia is associated with residual vascular risk.
Researchers investigated the efficacy of a new drug containing a naturally derived krill oil mixture for treatment of severe hypertriglyceridemia.
Inclisiran is a chemically synthesized small interfering RNA that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA.
The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH.
Researchers evaluated the association between baseline LDL-C and treatment with ezetimibe plus statins in post-acute coronary syndrome.
Children diagnosed with type 2 diabetes may face certain health challenges that grow worse over time and follow them into adulthood.
A clinical trial found that more lipid-lowering medications were prescribed when physicians were provided with pictorial information of their patients’ vascular age and carotid plaques.
Avoiding even 1 metabolic syndrome component might decrease the risk for a cardiovascular event or premature death, investigators suggest.
Patients with diabetes achieve LDL-C levels below recommended target goals, but high-intensity statin treatment appears frequently avoided.